The right generation EGFR TKI in first line: nothing less but a lifesaver!

Kim De Muynck (Brussels, Belgium)

Source: International Congress 2019 – Lung cancer?
Session: Lung cancer?
Session type: Lungs on fire
Number: 2096
Disease area: -

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kim De Muynck (Brussels, Belgium). The right generation EGFR TKI in first line: nothing less but a lifesaver!. International Congress 2019 – Lung cancer?

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Failure of EGFR TKI treatment: mechanisms and current strategies?
Source: ERS Research Seminar
Year: 2015

Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020

Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020

Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018

Tyrosine kinase inhibitors beyond progression: never, intercalating or forever?
Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies
Year: 2015

Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020

Immunotherapy in locally advanced and metastasized NSCLC: 2nd line, 1st line, liftoff!
Source: International Congress 2017 – The latest in lung cancer
Year: 2017

Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance.
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018

Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017

Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Year: 2017

Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic.
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018

Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Re-purposing TKI treatment
Source: International Congress 2016 – The future of tyrosin kinase inhibitors
Year: 2016

European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015

Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015

Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib?
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008